Organogenesis Holdings Inc.
Data quality: 100%
ORGO
NASDAQ
Manufacturing
Chemicals
$2.55
▼
$0.05
(-1.92%)
6 months return
—
Momentum
Neutral
5Y revenue growth
4.78%
Growth
Revenue Growth (5Y)
4.78%
Above sector avg (1.82%)
Revenue (1Y)17.04%
Earnings (1Y)4201.05%
FCF Growth (3Y)N/A
Quality
Return on Equity
15.17%
Above sector avg (-54.47%)
ROIC8.65%
Net Margin6.56%
Op. Margin7.92%
Safety
Debt / Equity
N/A
Current Ratio3.32
Interest Coverage19.59
Valuation
PE (TTM|NTM|2027)
7.97 | 8.97 | 7.93
Above sector avg (-1.50)
P/B Ratio1.16
EV/EBITDA3.86
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Revenue grew 4.78% annually over 5 years — modest growth
Earnings grew 4201.05% over the past year
ROE of 15.17% — decent returns on equity
Negative free cash flow of -24.46 M
P/E of 7.97 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 12.26%
Price History
Financial Trends
Analyst Price Target
1 analyst
Buy
+213.7%
upside to target
Current
$2.55
Consensus Target
$8.00
$8.00
Low
$8.00
High
Forecast
Forward P/E
8.97
Forward EPS
$0.29
Est. Revenue
506.60 M
Earnings Surprises
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -$0.29
·
Rev Est: 43.30 M
| Q12025 | Q22025 | Q32025 | Q42025 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|
| Reported | -$0.11 | -$0.06 | $0.18 | $0.40 | — | — |
| Estimate | -$0.03 | -$0.01 | $0.07 | $0.21 | -$0.29 | -$0.09 |
| Surprise | -254.67% | -491.00% | +153.57% | +90.52% | — | — |
Growth
Rev 5Y: 4.78% · Earnings 1Y: 4201.05%
Growth
Rev 5Y: 4.78% · Earnings 1Y: 4201.05%| Revenue Growth (1Y) | 17.04% | Revenue Growth (3Y) | 14.13% |
| Earnings Growth (1Y) | 4201.05% | Earnings Growth (3Y) | 173.66% |
| Revenue Growth (5Y) | 4.78% | Earnings Growth (5Y) | -20.96% |
Profitability
ROE: 15.17% · Net Margin: 6.56%
Profitability
ROE: 15.17% · Net Margin: 6.56%| Revenue (TTM) | 564.17 M | Net Income (TTM) | 37.03 M |
| ROE | 15.17% | ROA | 7.63% |
| Gross Margin | N/A | Operating Margin | 7.92% |
| Net Margin | 6.56% | Free Cash Flow (TTM) | -24.46 M |
| ROIC | 8.65% | FCF Growth (3Y) | N/A |
Safety
D/E: N/A · Current: 3.32
Safety
D/E: N/A · Current: 3.32| Debt / Equity | N/A | Current Ratio | 3.32 |
| Interest Coverage | 19.59 | Asset Turnover | 1.16 |
| Working Capital | 209.43 M | Tangible Book Value | 216.41 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: 7.97 · EV/EBITDA: 3.86
Valuation
P/E: 7.97 · EV/EBITDA: 3.86| P/E Ratio | 7.97 | Forward P/E | 8.97 |
| P/B Ratio | 1.16 | P/S Ratio | 0.52 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | 3.86 | Fwd EV/EBITDA | N/A |
| Forward P/S | 0.58 | Fwd Earnings Yield | 11.15% |
| FCF Yield | -8.29% | ||
| Market Cap | 295.23 M | Enterprise Value | 231.49 M |
Per Share
EPS: 0.15 · FCF/Share: -0.19
Per Share
EPS: 0.15 · FCF/Share: -0.19| EPS (Diluted TTM) | 0.15 | Revenue / Share | 4.39 |
| FCF / Share | -0.19 | OCF / Share | -0.08 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | -32.20% |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: -66.05% · CapEx/Rev: 2.51%
Efficiency
FCF Conv: -66.05% · CapEx/Rev: 2.51%| CapEx / Revenue | 2.51% | FCF Conversion | -66.05% |
| SBC-Adj. FCF | -36.15 M | Growth Momentum | 12.26 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 564.17 M | 482.04 M | 433.14 M | 450.89 M | 468.06 M |
| Net Income | 37.03 M | 861,000.0 | 4.95 M | 15.53 M | 94.90 M |
| EPS (Diluted) | 0.15 | -0.01 | 0.04 | 0.12 | 0.71 |
| Gross Profit | — | 366.30 M | 326.66 M | 345.87 M | 353.86 M |
| Operating Income | 44.69 M | -1.28 M | 12.53 M | 22.30 M | 72.92 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 44.54 M | 50.27 M | 44.38 M | 39.76 M | 30.74 M |
| SG&A Expenses | 326.24 M | 294.51 M | 269.75 M | 283.81 M | 250.20 M |
| D&A | 15.27 M | 13.62 M | — | — | — |
| Interest Expense | -2.28 M | 1.54 M | 2.19 M | 2.01 M | 7.24 M |
| Income Tax | 9.94 M | -3.67 M | 5.45 M | 4.75 M | -31.12 M |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 598.73 M | 497.89 M | 460.03 M | 449.36 M | 443.26 M |
| Total Liabilities | 164.81 M | 112.57 M | 181.36 M | 183.69 M | 201.22 M |
| Shareholders' Equity | 300.13 M | 262.90 M | 278.66 M | 265.67 M | 242.04 M |
| Total Debt | — | — | 66.56 M | 71.25 M | 74.06 M |
| Cash & Equivalents | 93.68 M | 135.57 M | 103.84 M | 102.48 M | 113.93 M |
| Current Assets | 362.19 M | 285.94 M | 225.04 M | 222.61 M | 226.98 M |
| Current Liabilities | 100.12 M | 77.48 M | 80.51 M | 75.02 M | 82.01 M |
Peer Comparison
vs Manufacturing sector median (1605 peers)
Compared with similar companies in Manufacturing
Peer Comparison
vs Manufacturing sector median (1605 peers) Compared with similar companies in Manufacturing| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 8.0 | -1.5 |
| P/B | 1.2 | 1.6 |
| ROE % | 15.2 | -54.5 |
| Net Margin % | 6.6 | -41.5 |
| Rev Growth 5Y % | 4.8 | 1.8 |
| D/E | — | 0.3 |
Strategy Scores
1 strategy matched
Strategy Scores
1 strategy matched
#116 of 245
Recent Activity
Entered
Price/Sales Ratio Focus (Ken Fisher)
Apr 12, 2026
{"event":"ticker_viewed","properties":{"ticker":"ORGO","listing_kind":"stock","pathname":"/stocks/orgo","exchange":"NASDAQ","country":"US"}}